Form 15-12G Sigyn Therapeutics, Inc.

July 16, 2026 6:03 AM EDT

 

 

 

    OMB APPROVAL
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB Number: 3235-0167
  Expires: August 31, 2027
  Estimated average burden hours per response ......... 1.50

 

FORM 15

 

CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.

 

Commission File Number 000-55575

 

SIGYN THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

2301 Historic Decatur Road, Suite 100

San Diego, California 92106

(619) 353-0800

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

 

Common Stock, $0.0001 Par Value

(Title of each class of securities covered by this Form)

 

None

(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

 

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

 

  Rule 12g-4(a)(1)  
  Rule 12g-4(a)(2)  
  Rule 12h-3(b)(1)(i)  
  Rule 12h-3(b)(1)(ii)  
  Rule 15d-6  
  Rule 15d-22(b)  

 

Approximate number of holders of record as of the certification or notice date: 120

 

 

 

 

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934 (Name of registrant as specified in charter) has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

 

Date: July 15, 2026 By: /s/ James A. Joyce
  Name: James A. Joyce
  Title: Chief Executive Officer

 

2 of 2

 



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

SEC Filings